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We are pleased to reply to Lazorwitz et al. [1]
letter response in regard to our manuscript
published in Advances in Therapy on Septem-
ber 2019 [2]. First, we commend the efforts of
Lazorwitz A. and colleagues in searching genetic
factors that may influence etonogestrel plasma
concentrations, especially for exploring Cyto-
chrome P450 (CYP) enzymes as they have tra-
ditionally been considered of little relevance for
the metabolism of progestogens.
The reasons why we decided not to compare
our results with theirs were: (a) structural dif-
ferences between progesterone and etonogestrel
(i.e., on position 17, Fig. 1) may alter CYP
specificity, (b) the endogenous nature of pro-
gesterone vs. the exogenous nature of etono-
gestrel and (c) the differences in the study
population, i.e., postmenopausal women vs.
contraceptive implant users. To be able to
compare our results with those of Lazorwitz
et al. [1], it must be assumed that both com-
pounds are metabolized in the exact same way.
More difficult to assume are the limitations
stated in ‘‘(b)’’ and ‘‘(c)’’. Postmenopausal
women and contraceptive implant users are not
comparable in terms of endogenous proges-
terone plasma levels. In addition, endogenous
progesterone may have different effects on
exogenous progesterone or etonogestrel meta-
bolism. These differences in the study design
and drug characteristics may explain why we
found an association between CYP2C19 phe-
notype and progesterone levels that was not
found in their study.
Nevertheless, their findings on CYP3A7*1C
are surprising. This CYP enzyme has been
reported to contribute in a minor extent to
progesterone metabolism [3]. However, their
findings are coherent, as the presence of this
variant leads to the expression of the silenced
fetal gene in adults [4]. The latter would
increase etonogestrel metabolism, explaining
the 23% lower plasma levels reported for
CYP3A7*1C carriers compared to wild type
patients. It would be of great interest to geno-
type our study population for this variant.
However, due to the low prevalence of this
variant and our relatively small sample size, it is
highly unlikely that we would observe signifi-
cant effects. In addition, we did not observe
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effects of weight on progesterone plasma levels.
This may be due to the low variability in weight
among our volunteers, probably caused by the
application of trial’s inclusion criteria.
In summary, both studies claim the rele-
vance of CYP enzymes in progestin (etono-
gestrel) and progesterone metabolism. The
extent to which this occurs must be demon-
strated in additional studies, i.e., the associa-
tions with CYP3A7*1C and CYP2C19
phenotype must be replicated.
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Fig. 1 Chemical structures of (a) left, progesterone and (b) right, etonogestrel. Images created with an image processing
software (created at http://molview.org/)
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